Rx Required
Tirzepatide
Compounded Tirzepatide. Prepared by a licensed 503A/503B pharmacy. Dual-action GIP/GLP-1 agonist targeting two hormone pathways for stronger appetite suppression and greater weight reduction.
Get Started →
One pathway wasn't enough.
So we target two.
Tirzepatide is a dual GIP/GLP-1 receptor agonist that works on two hormone pathways simultaneously. It suppresses appetite, reduces food noise, improves insulin sensitivity, and may produce stronger weight reduction than single-pathway GLP-1 medications alone.
Compounded by a licensed 503A/503B facility. Your dosing protocol is tailored to your history, tolerance, and goals through our async telehealth model. One weekly injection. $300 for your 2-month intro bundle ($150/mo), then $360/mo ongoing. No membership. No subscription.
02.
Two pathways. One protocol.
Dual Hormone Action
Targets both GIP and GLP-1 receptors simultaneously. Two metabolic pathways working together for stronger, more comprehensive appetite control.
Greater Weight Reduction
In SURMOUNT-1, tirzepatide 15 mg produced ~21% average body-weight reduction over 72 weeks (NEJM 2022). The dual-agonist mechanism may outperform single-pathway GLP-1 medications.
Metabolic Optimization
Enhanced insulin sensitivity and glucose regulation through two distinct receptor pathways. Your metabolism recalibrates at a deeper level.
Food Noise Elimination
The constant mental chatter about food goes quiet. Not willpower. Not discipline. Biology, corrected on two fronts.
Cardiovascular Support
Emerging data supports cardiovascular benefits including improved lipid profiles and reduced inflammatory markers alongside weight reduction.
03.
Your body responds.
How Compounded Tirzepatide Works
04.
Already on GLP-1s?
We accept clients at any dose. Transfer your protocol to IVUSE+ and continue without interruption.
Proof of prior treatment required.
Refill Request →
06.
Your clinician reads every intake.
What you should know before starting.
Review the complete safety profile, contraindications, and clinical guidance before beginning your protocol. Your prescribing clinician will review this with you during your consultation.
Read Full Safety Information →What You Need to Know About Compounded Tirzepatide
How much does compounded Tirzepatide cost?
IVUSE+ offers compounded Tirzepatide starting at $300 for a 2-month intro bundle ($150/mo effective rate). Ongoing monthly refills are $360/mo flat. No membership fees, no subscription, no hidden costs. The price includes medication, telehealth consultation, and shipping.
How is Tirzepatide different from Semaglutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, targeting two hormone pathways instead of one. This dual-action mechanism may produce stronger appetite suppression and greater weight reduction. In the SURMOUNT-1 trial, tirzepatide 15 mg produced roughly 21% average body-weight reduction over 72 weeks (Jastreboff et al., NEJM 2022), compared with roughly 15% for single-pathway GLP-1 compounded Semaglutide (STEP 1). Individual results vary.
Is compounded Tirzepatide FDA-approved?
The active ingredient (tirzepatide) has FDA approval. Compounded formulations are prepared by a licensed 503A/503B pharmacy and are not FDA-approved as finished products. This is standard for all compounded medications.
Do I need a prescription?
Yes. A telehealth consultation with a licensed clinician is required. IVUSE+ uses an async telehealth model: complete a health assessment online, and a licensed provider reviews your history, medications, and goals to determine eligibility.
What are the common side effects?
Common side effects include nausea, diarrhea, decreased appetite, and vomiting during the initial adjustment period. These typically subside within the first month as your body acclimates to the dual-agonist mechanism. Dosing starts at 2.5mg weekly and is gradually increased.
How long until I see results?
Most patients notice reduced appetite and food noise within 2-4 weeks. Visible weight reduction typically begins by weeks 4-8 as dosing is titrated up. In the SURMOUNT-1 trial, tirzepatide 15 mg produced roughly 21% average body-weight reduction over 72 weeks (NEJM 2022); individual results vary.
Your Protocol Starts Here.
Compounded Tirzepatide. Dual-action dosing. $360/mo, no membership, no subscription.
Get Started →Individual results vary. Compounded medications are not FDA-approved. A telehealth consultation with a licensed clinician is required before any prescription is issued. IVUSE+ does not guarantee specific weight loss outcomes. Medication is compounded by a licensed 503A/503B compounding facility.
*Weight-reduction figure reflects tirzepatide 15 mg vs. placebo in the SURMOUNT-1 randomized trial (Jastreboff AM, et al. N Engl J Med 2022;387:205-216). Compounded tirzepatide is not the studied finished product; individual results vary.
Medically reviewed by the IVUSE+ Clinical Team · Last reviewed July 2026
